福元医药发布上半年业绩，归母净利润2.68亿元，下降7.83%

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) reported a decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 1.634 billion yuan, a decrease of 1.30% year-on-year [1] - The net profit attributable to shareholders of the listed company was 268 million yuan, down 7.83% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 258 million yuan, a decrease of 6.02% year-on-year [1] - Basic earnings per share were 0.56 yuan [1]